Skip to main content

Drug Interactions between clarithromycin and ibutilide

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Major

clarithromycin ibutilide

Applies to: clarithromycin and ibutilide

GENERALLY AVOID: Macrolide antibiotics including azithromycin, clarithromycin, and erythromycin have been associated with prolongation of the QT interval and infrequent cases of cardiac arrhythmia. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. In general, the risk of an individual agent or a combination of agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances (e.g., hypokalemia, hypomagnesemia). Elderly patients may also be more susceptible to drug-associated effects on the QT interval.

MANAGEMENT: The use of macrolide antibiotics in patients receiving class IA or class III antiarrhythmic agents antiarrhythmic agents should generally be avoided unless benefits are anticipated to outweigh the risks. Caution and clinical monitoring are recommended if these agents are prescribed together, especially to patients with underlying risk factors. Patients should be advised to seek medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitations, irregular heartbeat, shortness of breath, or syncope.

References (6)
  1. (2002) "Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals
  2. (2002) "Product Information. Biaxin (clarithromycin)." Abbott Pharmaceutical
  3. "Product Information. Eryc (erythromycin)." Parke-Davis
  4. Gitler B, Berger LS, Buffa SD (1994) "Torsades de pointes induced by erythromycin." Chest, 105, p. 368-72
  5. Lee KL, Jim MH, Tang SC, Tai YT (1998) "QT prolongation and torsades de pointes associated with clarithromycin." Am J Med, 104, p. 395-6
  6. (2003) "Product Information. Erythrocin Lactobionate (erythromycin)." Abbott Pharmaceutical

Drug and food interactions

Minor

clarithromycin food

Applies to: clarithromycin

Grapefruit juice may delay the gastrointestinal absorption of clarithromycin but does not appear to affect the overall extent of absorption or inhibit the metabolism of clarithromycin. The mechanism of interaction is unknown but may be related to competition for intestinal CYP450 3A4 and/or absorptive sites. In an open-label, randomized, crossover study consisting of 12 healthy subjects, coadministration with grapefruit juice increased the time to reach peak plasma concentration (Tmax) of both clarithromycin and 14-hydroxyclarithromycin (the active metabolite) by 80% and 104%, respectively, compared to water. Other pharmacokinetic parameters were not significantly altered. This interaction is unlikely to be of clinical significance.

References (1)
  1. Cheng KL, Nafziger AN, Peloquin CA, Amsden GW (1998) "Effect of grapefruit juice on clarithromycin pharmacokinetics." Antimicrob Agents Chemother, 42, p. 927-9

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.


Report options

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.